

# Synthesis and Antimicrobial Activity of Furochromone, Benzofuran and Furocoumarin Derivatives Bearing Sulfonyl Moiety

Sadia A. Hessein,<sup>1</sup> Marwa A. M. Sh. El-Sharief,<sup>2,3</sup> Samir Y. Abbas,<sup>4,\*</sup> Hamdy Kh. Thabet,<sup>5</sup> Yousry A. Ammar<sup>5,\*</sup>

<sup>1</sup> Chemistry Department, Faculty of Science, Al-Azhar University (Girls), Nasr City, Cairo, Egypt

<sup>2</sup> Applied Organic Chemistry Department, National Research Centre, Cairo, Egypt

<sup>3</sup> Faculty of Science and Arts, Mohail Asser, King Khalid University, Saudi Arabia

<sup>4</sup> Organometallic and Organometalloid Chemistry Department, National Research Centre, Cairo, Egypt

<sup>5</sup> Chemistry Department, Faculty of Science, Al-Azhar University, Nasr City, Cairo, Egypt

\* Corresponding authors' e-mail addresses: samiryoussef98@yahoo.com; yossry@yahoo.com

RECEIVED: January 2, 2016 \* REVISED: March 8, 2016 \* ACCEPTED: March 14, 2016


**Abstract:** New visnagin-9-sulfonamide derivatives **3** and **4a–c** were synthesized through the reaction of visnagin-9-sulfonyl chloride **2** with amino compounds. Acetylation of compounds **4b** and **4c** gave the monoacetyl and diacetyl derivatives **5** and **6**, respectively. Diazotization reaction of compound **4b** afforded the corresponding benzotriazole derivative **8**. Pyrazole and thiopyrimidine derivatives **9** and **10** were obtained *via* the opening of pyrone ring upon reaction of compound **3** with hydrazine hydrate and thiourea, respectively. In addition, hydrolysis of compound **3** with potassium hydroxide furnished the visnaginone derivative **11** which used as starting material for synthesizing benzofuran derivatives **12–14** and bergaptene derivatives **15–17**. The synthesized compounds were tested for antimicrobial activity. Furochromone derivatives **3**, **4a–c**, **5**, **6** and **8** (visnagin-9-sulfonamide derivatives) demonstrate moderate antibacterial and antifungal activities compared with the antibacterial and antifungal activities of the standard drugs. Benzofuran derivatives **11–14** (visnaginone derivatives) showed the lowest antimicrobial activity among all the compounds investigated in this study. Furocoumarin derivatives **15a,b**, **16** and **17** (furobenzopyransulfonamide [bergaptensulfonamides]) are moderately active against all the tested strains.

**Keywords:** visnagine (furochromones), visnaginone (benzofurans), bergaptene (furocoumarins), sulfonamides, antimicrobial activity.

## INTRODUCTION

**D**UE to the development of the bacterial resistant to many currently available antibiotic treatments, there is increasing interest in the discovery of new antimicrobial agents.<sup>[1–3]</sup> Visnagin (4-methoxy-7-methyl-5H-furo[3,2-g]chromen-5-one) is one of the essential chemical constituents of the fruits and seeds of *Ammi visnaga*, family Umbelliferae and it is known to possess antispasmodic properties to the ureter and bile duct, treats angina, whooping cough, gall bladder and renal colic.<sup>[4]</sup> It is considered as a potent coronary vasodilator as well as its role in treating bronchial asthma.<sup>[5,6]</sup> Molecules with the chromone scaffold possess wide range of biological activities, including antioxidant, antifungal, antimicrobial, antiallergenic,

anti-inflammatory, antiproliferative and antitumor activities.<sup>[7–10]</sup> Chromones represent an attractive source of medicinally interesting compounds due to their low toxicity. Many benzofurans are based on the chromone structure and they have been found to possess several therapeutically interesting biological activities.<sup>[11]</sup> Sulfonamides are bacteriostatic antimicrobial agents and they are most effective in early stages of acute infections when organisms multiply rapidly. Sulfonamide-based compounds were extensively used for antibacterial agents and they are the second antimicrobial agents.<sup>[12–14]</sup> These derivatives are still widely used today for the treatment of various bacterial, protozoal and fungal infections<sup>[15]</sup> and are the first effective chemotherapeutic agent used in safe therapeutic dosage ranges.<sup>[16]</sup> Based on the above mentioned observations and



**Scheme 1.** Synthesis of visnagin-9-sulfonamide derivatives **3** and **4a-c** (Furochromone derivatives).

in continuation of our research program on the field of sulfonamide derivatives,<sup>[17–21]</sup> antimicrobial and antifungal agents,<sup>[22–25]</sup> we would like to report the synthesis of furochromone, benzofuran and furocoumarin derivatives containing sulfonamide moiety as a trial to obtain novel class of antibacterial and antifungal agents.

## RESULTS AND DISCUSSION


### Chemistry

The starting material, visnagin-9-sulfonyl chloride **2**<sup>[26]</sup> was prepared from the reaction of visnagin **1** with chlorosulfonic acid. The reactivity of sulfonylchloride derivative **2** towards nitrogenous compounds was discussed. Thus, interaction of **2** with piperazine as secondary amine and *o*-phenatidine, *o*-phenylenediamine and 4,4'-diaminobiphenyl gave the corresponding sulfonamide derivatives **3** and **4a-c**, respectively (Scheme 1). The structures of **3** and **4** have been assigned as a reaction product on the basis of analytical and spectral data. IR spectrum of **4a** as an example displayed absorption bands at 3239 and 1661 cm<sup>-1</sup> due to NH and C=O functional groups, respectively. <sup>1</sup>H NMR spectrum exhibited two sharp singlet signals at 2.40 ppm and 3.89 ppm assignable to CH<sub>3</sub> and OCH<sub>3</sub> protons, another triplet and quartet signals at 1.21 and 4.22 ppm specific for ethoxy protons. Other singlets were observed at 6.07 ppm

corresponding for chromone-H proton, multiplet signals in 6.69–7.95 ppm region owing to aromatic protons, two doublets for furan protons as well as a broad signal at 8.61 ppm due to NH proton. Mass spectrum showed a molecular ion peak at *m/z* = 429, corresponding to a molecular formula C<sub>21</sub>H<sub>19</sub>NO<sub>7</sub>S.

Compounds **4b** and **4c** are considered as key intermediates for the synthesis of some sulfonamide derivatives. Thus, treatment of **4b** and **4c** with acetic anhydride produced the corresponding acetyl and diacetyl derivatives **5** and **6**, respectively (Scheme 2). Spectral data of the isolated product was in complete agreement with the expected structures. IR spectrum of compound **6** showed absorption bands at 3121, 1710 and 1662 cm<sup>-1</sup> corresponding to NH and 2C=O functional groups, respectively. <sup>1</sup>H NMR spectrum showed five singlet signals at 1.99, 2.32, 4.06 and 6.19 ppm characteristic for 3CH<sub>3</sub>, OCH<sub>3</sub> and chromone-H protons, respectively. In addition, treatment of **4b** with nitrous acid produced benzotriazole derivative **8** through the formation of diazonium chloride salt **7** followed by intramolecular cyclization *via* HCl elimination (Scheme 2). The structure of **8** was confirmed by elemental analysis and spectral data. IR spectrum exhibited band at 1668 cm<sup>-1</sup> corresponding for C=O group.

The reactivity of sulfonamide derivative **3** against binucleophilic reagents was investigated. Thus, treatment of **3** with hydrazine hydrate in ethanol under reflux afforded




**Scheme 2.** Syntheses of monoacetyl and diacetyl derivatives **5** and **6**, and benzotriazole derivative **8**.


in good yield a product that was identified as pyrazole derivative **9**. Formation of compound **9** is assumed to take place *via* nucleophilic attack of hydrazine which caused ring opening of  $\gamma$ -pyrone which readily undergo intermolecular cyclization by water elimination (Scheme 3). IR spectrum showed lack the band corresponding for carbonyl functional group and showed broad band around 3392 cm<sup>-1</sup> due to OH and NH functional groups. <sup>1</sup>H NMR spectrum revealed a singlet signal at 6.45 ppm characteristic for pyrazole proton also, another broad singlet signals at 10.41, 11.14 ppm due to NH and OH protons. Similarly, interaction of **3** with thiourea in ethanol containing anhydrous potassium carbonate led to ring opening. The thiopyrimidine derivative **10** was assigned for the reaction product on the basis of its elemental analysis and spectral data obtained. IR spectrum lacked an absorption band due to a carbonyl functional group and revealed absorption bands at: 3443

and 3221 cm<sup>-1</sup> characteristic for OH and NH functional groups, respectively. <sup>1</sup>H NMR spectrum displayed signals at 7.34, 9.59 and 13.05 ppm assignable to pyrimidine-H, NH and OH protons, respectively.

It is interesting in this connection that the hydrolysis of sulfonamide derivative **3** with potassium hydroxide caused opening  $\gamma$ -pyrone ring and the product of this reaction was identified on the basis of its spectral data as visnaginone derivative **11**. IR spectrum revealed the presence of OH and NH stretching bands at: 3165 and 3124 cm<sup>-1</sup> and C=O band at: 1666 cm<sup>-1</sup>. Also, its <sup>1</sup>H NMR spectrum supported its structure, as it revealed the piperazine ring protons at 2.68–3.33 and two broad signals at 10.26 and 13.13 ppm assignable to NH and OH protons, respectively. Treatment of **11** with dimethylformamide-dimethylacetal (DMF-DMA) in toluene under reflux afforded the corresponding enaminone derivative **12**. IR spectrum displayed broad absorption



**Scheme 3.** Syntheses of pyrazole derivative **9** and thiopyrimidine derivative **10**.



**Scheme 4.** Synthesis of benzofuran derivatives **11–14** (Visnaginone derivatives).

band around  $3200\text{ cm}^{-1}$  due to OH and NH functions and at  $1668\text{ cm}^{-1}$  due to conjugated C=O functional group. Mass spectrum showed a molecular ion peak at  $m/z = 409$ , corresponding to a molecular formula  $\text{C}_{18}\text{H}_{23}\text{N}_3\text{O}_6\text{S}$ . In addition, condensation of visnaginone **11** with 4-chlorobenzaldehyde gave the corresponding styryl derivative **13** which was condensed with phenylhydrazine to give the pyrazoline derivative **14** (Scheme 4). IR spectrum of compound **14** has no absorption band characteristic to C=O group and it revealed the presence of C=N band at  $1597\text{ cm}^{-1}$ .  $^1\text{H}$  NMR spectrum showed the presence of signals corresponding for piperazine and pyrazoline protons in addition to the presence of two broad signals at: 9.36 and 14.17 for NH and OH, respectively.


In view of the growing biological importance of furocoumarin, particularly bergapten, it was of interest to synthesize some bergaptensulfonamides on the hope of obtaining more antimicrobial agents. Thus, cyclization of **11** with malononitrile or ethyl cyanoacetate in the presence of piperidine afforded furobenzopyransulfonamide derivatives **15a,b**. Both elemental analysis and spectral data of the isolated products were in assignment with the proposed structure. IR spectra of **15a,b** showed bands around  $2200\text{ cm}^{-1}$  due to C≡N functional group. Their  $^1\text{H}$  NMR spectra exhibited two singlet signals around 2.42 and 4.10 ppm specific for  $\text{CH}_3$  and  $\text{OCH}_3$  protons. Interaction of **15b** with elemental sulfur in ethanolic morpholine yielded thiophene derivative **16** *via* thiation of methyl group followed by intermolecular cyclization (Scheme 5). Its IR spectrum

showed the disappearance of C≡N group and revealed bands at  $3299$  and  $3414\text{ cm}^{-1}$  ( $\text{NH}_2$ , NH). In addition, interaction of compound **15b** with 4-methoxybenzylidene malononitrile furnished benzopergapten derivative **17**. The formation of benzopergapten derivative **17** can be assumed *via* addition of methyl group in **15b** to the activated double bond of arylidene to form intermediate. Cyclization of the latter intermediate formed another intermediate which subjected to elimination of HCN to form **17** (Scheme 5).

### Antibacterial and Antifungal Activities

The synthesized compounds were tested *in vitro* for antibacterial and antifungal activities by the agar diffusion method against the following strains: two Gram-positive bacteria, *Staphylococcus aureus* NCTC-7447 and *Bacillus cereus* ATCC-14579; two Gram-negative bacteria, *Pseudomonas aeruginosa* IMRU-70, and *Escherichia coli* NCTC-289; and three Fungi, *Aspergillus ochraceus* Wilhelm AUCC-230, *Penicillium chrysogenum thom* AUCC-530 and *Candida albicans* AUCC-420. The results were summarized in Table 1. Most of the synthesized compounds exhibited various antimicrobial activity towards all the micro-organisms used.

Certain aspects of the structure activity relationships of the prepared compounds were clearly highlighted. The results of the antimicrobial screening demonstrated the following assumptions about the structural activity relationship (SAR). Incorporating piperazin-1-ylsulfonyl moiety in position 9 of visnagine as in structure **3** had a detrimental effect on antimicrobial activity. Visnagin-9-piperazin-1-ylsulfonyl **3**



Scheme 5. Synthesis of furocoumarin derivatives **15a,b**, **16** and **17** (furobenzopyransulfonamide [bergaptensulfonamides]).

**Table 1.** Antimicrobial activity of the synthesized compounds against the pathological organisms expressed as inhibition diameter zones in millimeters (mm) based on well diffusion assay

Compd. No.	Gram positive bacteria		Gram negative bacteria			Fungi	
	<i>S. aureus</i>	<i>B. cereus</i>	<i>P. aeruginosae</i>	<i>E. coli</i>	<i>A. o. wilhelm</i>	<i>P. e. thom</i>	<i>C. albicans</i>
3	5	10	6	12	13	5	0
4a	12	13	17	19	6	12	13
4b	13	15	16	18	14	14	6
4c	14	18	19	20	19	18	5
5	19	0	9	5	5	5	8
6	9	8	8	10	18	10	9
8	10	6	11	18	0	0	0
11	5	0	0	0	0	8	3
12	9	5	0	5	0	0	0
13	4	8	5	5	4	0	5
14	0	4	0	5	4	0	17
15a	6	8	4	7	9	0	4
15b	5	9	5	8	8	0	5
16	8	5	8	9	8	0	0
17	8	7	7	8	7	0	0
Chloramphenicol	34	37	34	38	-----	-----	-----
Terbinafin	-----	-----	-----	-----	35	37	32

showed moderately active against all the tested strains. Changing the substituent on sulfonamide at position C-9 of visnagine from 2-ethoxyphenyl to 2-aminophenyl to 4-aminobiphenyl (**4a** → **4b** → **4c**) to show the difference between each substituent on the effect of the antimicrobial activity was carried out. Compound **4c** showed more activity than its analogues and showed high activities against all the tested strains. Incorporating sulfonamide-phenyl-acetamide moiety in position 9 of visnagine as in structure **5** did not improve the antimicrobial activity. Compound **5** showed moderately active against all the tested strains. Similarly, incorporating sulfonamide-biphenyl-4-yl-acetamide moiety in position 9 of visnagine as in structure **6** showed little improvement on antimicrobial activity. Compound **6** showed moderate activity against all the tested organisms. Surprising, incorporating 1*H*-benzo[*d*][1,2,3]triazol-1-ylsulfonyl moiety in position 9 of visnagine as in structure **8** did not showed remarkable improvement on the antimicrobial activity. Compound **8** showed moderately activity against all the tested bacteria and no activity against all the tested fungi. Broken  $\gamma$ -pyrone ring of visnagine as in structure **11** resulted in the lowest antimicrobial activity among all the investigated compounds. Visnaginone derivative **11** showed no activity against most of the tested bacteria and fungi. Treatment of **11** with dimethylformamide-dimethylacetal did not improve the antimicrobial activity. Compound **12** showed no activity against most of the tested bacteria and fungi. In addition, condensation of visnaginone **11** with 4-chlorobenzaldehyde did not improve the antimicrobial activity. Styryl

derivative **13** showed no activity against most of the tested bacteria and fungi. Moreover, condensation of styryl derivative **13** with phenylhydrazine did not improve the antimicrobial activity. Pyrazole derivative **14** showed high activity against *C. albicans* only and no activity against most of the tested bacteria and fungi. Formation of furocoumarin (furobenzopyransulfonamide [bergaptensulfonamides]) **15a,b** showed moderately active against all the tested strains. Treatment of **15b** with sulfur or aryledine did not improve the antimicrobial activity.

## CONCLUSIONS

Derivatives of furochromone, benzofuran and furocoumarin which bearing sulfonyl moiety were synthesized in order to evaluate their antibacterial and antifungal activities. Regarding the effect of each derivative against bacterial and fungal strains, results of antimicrobial activity in this study revealed that: Derivatives of visnagine with piperazin-1-yl-sulfonyl moiety in position **9** showed moderate activity against all the tested strains. Changing the substituent at position C-9 of visnagine from *N*-(2-ethoxyphenyl)-sulfonamide to *N*-(2-aminophenyl)-sulfonamide or *N*-(4-aminobiphenyl)-sulfonamide improved the antimicrobial activity. Besides, *N*-(4-aminobiphenyl)-sulfonamide moiety showed higher activity against all the tested strains. Incorporating sulfonamide-phenyl-acetamide, sulfonamide-biphenyl-4-yl-acetamide or 1*H*-benzo[*d*][1,2,3]triazol-1-ylsulfonyl moieties in position 9 of visnagine did not improve the antimicrobial activity. Broken  $\gamma$ -pyrone ring of visnagine

resulted in the lowest antimicrobial activity among all the compounds investigated in this study. Formation of fluorocoumarin (furobenzopyran-sulfonamide [bergapten-sulfonamides]) showed moderate activity against all the tested strains.

## EXPERIMENTAL

Melting points were determined on a digital Gallen-Kamp MFB-595 instrument and were uncorrected. IR spectra (KBr) were measured using a Jasco FT/IR-300E spectrometer.  $^1\text{H}$  NMR were recorded on a Bruker (500 MHz) spectrometer using TMS as an internal standard; chemical shifts are reported as  $\delta$ /ppm units. Mass spectra were performed on a Shimadzu GSMS-QP 1000 Ex mass spectrometer at 70 eV. The elemental analyses were carried out at the Micro-analytical Center, Cairo University, Cairo, Egypt. Antimicrobial screening was carried out in Biochemistry Department Faculty of Agriculture, Al-Azhar University.

### General Procedure for the Synthesis of Visnagin-9-sulfonamide Derivatives 3 and 4a–c

A mixture of **2** (0.01 mol), appropriate amines (namely; piperazine, *o*-phenatidine, *o*-phenylenediamines and 4,4'-diaminobiphenyl) (0.01mol) and pyridine (1 mL) in dry benzene (25 mL) was heated under reflux for 2h, the solvent was evaporated and the resulting solids were crystallized from ethanol to give the corresponding compounds **3** and **4a–c**.

#### 4-Methoxy-7-methyl-9-(piperazin-1-ylsulfonyl)-5H-furo[3,2-g]chromen-5-one (**3**)

White crystals; m.p. > 300 °C; IR  $\tilde{\nu}/\text{cm}^{-1}$ : 3245 (NH), 1665 (C=O);  $^1\text{H}$  NMR (DMSO- $d_6$ )  $\delta$ /ppm: 2.56 (s, 3H, CH<sub>3</sub>), 2.74–3.56 (m, 8H, piperazine moiety), 3.67 (s, 3H, OCH<sub>3</sub>), 6.45 (s, 1H, pyrone), 6.92–7.80 (m, 2H, furan-H), 9.88 (br, 1H, NH, D<sub>2</sub>O-exchangeable); MS ( $m/z$ , %): 378 (M<sup>+</sup>, 54), 187 (100); Anal. Calcd. for C<sub>17</sub>H<sub>18</sub>N<sub>2</sub>O<sub>6</sub>S (378.40): C, 53.96; H, 4.79; N, 7.40. Found: C, 54.11; H, 4.64; N, 7.56.

#### *N*-(2-Ethoxyphenyl)-4-methoxy-7-methyl-5-oxo-5H-furo[3,2-g]chromene-9-sulfonamide (**4a**)

Yellow sheets; m.p. 192–194 °C; IR  $\tilde{\nu}/\text{cm}^{-1}$ : 3239 (NH), 1661 (C=O);  $^1\text{H}$  NMR (CDCl<sub>3</sub>)  $\delta$ /ppm: 1.21 (t, 3H,  $J$  = 6.85 Hz, CH<sub>3</sub>-ethyl), 2.40 (s, 3H, CH<sub>3</sub>), 3.89 (s, 3H, OCH<sub>3</sub>), 4.22 (q, 2H,  $J$  = 6.85 Hz, CH<sub>2</sub>-ethyl), 6.07 (s, 1H, H<sub>3</sub>-pyrone), 6.69–7.92 (m, 6H, 4Ar-H + 2furan-H), 8.61 (br, 1H, NH; D<sub>2</sub>O-exchangeable); MS ( $m/z$ , %): 429 (M<sup>+</sup>, 38); Anal. Calcd. for C<sub>21</sub>H<sub>19</sub>NO<sub>7</sub>S (429.45): C, 58.73; H, 4.46; N, 3.26. Found: C, 58.62; H, 4.51; N, 3.24.

#### *N*-(2-Aminophenyl)-4-methoxy-7-methyl-5-oxo-5H-furo[3,2-g]chromene-9-sulfonamide (**4b**)

Yellow powder; m.p. 171–173 °C; IR  $\tilde{\nu}/\text{cm}^{-1}$ : 3211, 3123 (NH, NH<sub>2</sub>), 1673 (C=O);  $^1\text{H}$  NMR (CDCl<sub>3</sub>)  $\delta$ /ppm: 2.42 (s, 3H, CH<sub>3</sub>), 3.94 (s, 3H, OCH<sub>3</sub>), 4.69 (br, 2H, NH<sub>2</sub>; cancelled with D<sub>2</sub>O); 6.11 (s, 1H, H<sub>3</sub>-pyrone), 6.55–7.72 (m, 6H, 4Ar-H + 2furan-H), 9.61 (s, 1H, NH; D<sub>2</sub>O-exchangeable); MS ( $m/z$ , %): 400 (M<sup>+</sup>, 21), 229 (17), 201 (33), 107 (100); Anal. Calcd. for C<sub>19</sub>H<sub>16</sub>O<sub>6</sub>N<sub>2</sub>O<sub>6</sub>S (400.41): C, 56.99; H, 4.03; N, 7.00. Found: C, 56.87; H, 4.09; N, 7.13.

#### *N*-(4'-Aminobiphenyl-4-yl)-4-methoxy-7-methyl-5-oxo-5H-furo[3,2-g]chromene-9-sulfonamide (**4c**)

Pink crystals; m.p. 240–242 °C; IR  $\tilde{\nu}/\text{cm}^{-1}$ : 3238, 3173 (NH, NH<sub>2</sub>), 1663 (C=O);  $^1\text{H}$  NMR (DMSO- $d_6$ )  $\delta$ /ppm: 2.39 (s, 3H, CH<sub>3</sub>), 4.01 (s, 3H, OCH<sub>3</sub>), 4.77 (br, 2H, NH<sub>2</sub>; D<sub>2</sub>O-exchangeable); 6.17 (s, 1H, H<sub>3</sub>-pyrone), 6.55–7.70 (m, 10 H, 8Ar-H + 2furan-H), 9.61 (s, 1H, NH; D<sub>2</sub>O-exchangeable); MS ( $m/z$ , %): 476 (M<sup>+</sup>, 34), 184 (100); Anal. Calcd. for C<sub>25</sub>H<sub>20</sub>N<sub>2</sub>O<sub>6</sub>S (476.50): C, 63.02; H, 4.23; N, 5.88. Found: C, 63.14; H, 4.31; N, 5.68.

### General Procedure for Acetylation of Compounds 4b and 4c

The solution of **4b** or **4c** (0.01 mol) in acetic anhydride (10 mL) was heated under reflux for 2h. The reaction mixture was cooled and the solid product collected and crystallized from proper solvent to give **5** and **6**, respectively.

#### *N*-(2-(4-Methoxy-7-methyl-5-oxo-5H-furo[3,2-g]chromene-9-sulfonamido)phenyl)acetamide (**5**)

Yellow powder, the solid was crystallized from toluene; m.p. 186–188 °C; IR  $\tilde{\nu}/\text{cm}^{-1}$ : 3271, 3160 (2NH), 1714, 1664 (2 C=O);  $^1\text{H}$  NMR (DMSO- $d_6$ )  $\delta$ /ppm: 2.22 (s, 3H, CH<sub>3</sub>), 2.52 (s, 3H, CH<sub>3</sub>), 4.18 (s, 3H, OCH<sub>3</sub>), 6.09 (s, 1H, H<sub>3</sub>-pyrone), 6.96–7.43 (m, 7H, 4Ar-H + 2furan-H + NH), 9.45 (br, 1H, NH, D<sub>2</sub>O-exchangeable); MS ( $m/z$ , %): 442 (M<sup>+</sup>, 43); Anal. Calcd. for C<sub>21</sub>H<sub>18</sub>N<sub>2</sub>O<sub>7</sub>S (442.44): C, 57.01; H, 4.10; N, 6.33. Found: C, 57.10; H, 4.20; N, 6.40.

#### *N*-Acetyl-*N*-(4'-(4-methoxy-7-methyl-5-oxo-5H-furo[3,2-g]chromene-9-sulfonamido) biphenyl-4-yl)acetamide (**6**)

White crystals; the solid was crystallized from ethanol; m.p. 260–262 °C; IR  $\tilde{\nu}/\text{cm}^{-1}$ : 3121 (NH), 1710, 1662 (C=O);  $^1\text{H}$  NMR (DMSO- $d_6$ )  $\delta$ /ppm: 1.99 (s, 3H, CH<sub>3</sub>), 2.32 (s, 6H, 2COCH<sub>3</sub>), 4.06 (s, 3H, OCH<sub>3</sub>), 6.19 (s, 1H, H<sub>3</sub>-pyrone), 7.25–8.24 (m, 11H, 8Ar-H + 2furan-H + NH); MS ( $m/z$ , %): 560 (M<sup>+</sup>, 51); Anal. Calcd. for C<sub>29</sub>H<sub>24</sub>N<sub>2</sub>O<sub>8</sub>S (560.58): C, 62.13; H, 4.32; N, 5.00. Found: C, 62.20; H, 4.30; N, 4.80.

**9-(1H-benzo[d][1,2,3]triazol-1-ylsulfonyl)-4-methoxy-7-methyl-5H-furo[3,2-g]chromen-5-one (8)**

A compound of **4b** was dissolved in dil HCl (10 mL) then cooled to 0 °C with stirring. A freshly solution of sodium nitrite (0.01 mol in 5 mL H<sub>2</sub>O) was gradually added. The solution was stirring for further 2h., then the solid that formed was filtered off and crystallized from ethanol as white crystals; m.p. 150–151 °C; IR  $\tilde{\nu}/\text{cm}^{-1}$ : 1668 (C=O); <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta/\text{ppm}$ : 2.15 (s, 3H, CH<sub>3</sub>), 3.87 (s, 3H, OCH<sub>3</sub>), 6.01 (s, 1H, H<sub>3</sub>-pyrone), 7.19–8.11 (m, 6H, 4Ar-H + 2furan-H); MS (*m/z*, %): 411 (M<sup>+</sup>, 34); Anal. Calcd. for C<sub>19</sub>H<sub>13</sub>N<sub>3</sub>O<sub>6</sub>S (411.39): C, 55.47; H, 3.19; N, 10.21. Found: C, 55.60; H, 3.32; N, 10.43.

**4-Methoxy-5-(5-methyl-1H-pyrazol-3-yl)-7-(piperazin-1-ylsulfonyl)-benzofuran-6-ol (9)**

A mixture of **3** (0.01 mol) and hydrazine hydrate (0.012 mol) in ethanol (30 mL) was heated under reflux for 3h, the reaction mixture was cooled and the solid was collected and recrystallized from ethanol as yellow powder; m.p. 208–210 °C; IR  $\tilde{\nu}/\text{cm}^{-1}$ : 3392 (br, OH/ 2NH), 2949 (CH-aliph.), 1598 (C=N); <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>)  $\delta/\text{ppm}$ : 2.56 (s, 3H, CH<sub>3</sub>), 2.74–3.56 (m, 8H, piperazine moiety), 3.67 (s, 3H, OCH<sub>3</sub>), 6.45 (s, 1H, pyrazole), 6.92–7.80 (m, 3H, 2furan-H + NH), 10.41 (br, 1H, NH, D<sub>2</sub>O-exchangeable), 11.14 (br, 1H, OH; D<sub>2</sub>O-exchangeable); MS (*m/z*, %): 392 (M<sup>+</sup>, 61); Anal. Calcd. for C<sub>17</sub>H<sub>20</sub>N<sub>4</sub>O<sub>5</sub>S (392.43): C, 52.03; H, 5.14; N, 14.28. Found: C, 52.22; H, 5.33; N, 14.10.

**4-(6-Hydroxy-4-methoxy-7-(piperazin-1-ylsulfonyl)benzofuran-5-yl)-6-methylpyrimidine-2(1H)-thione (10)**

A mixture of **3** (0.01 mol), thiourea (0.012 mol) and potassium carbonate (0.5g) in ethanol (30 mL) was heated under reflux for 3h, the reaction mixture was cooled then acidified with dil. HCl. The solid product was collected and recrystallized from ethanol to give **10** as yellow powder; m.p. 138–140 °C; IR  $\tilde{\nu}/\text{cm}^{-1}$ : 3443, 3221 (br, OH/ 2NH), 2925 (CH-aliph.), 1593 (C=N), 1280 (C=S); <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>)  $\delta/\text{ppm}$ : 2.51 (s, 3H, CH<sub>3</sub>), 2.56–3.16 (m, 8H, piperazine), 3.41 (s, 3H, OCH<sub>3</sub>), 7.34 (s, 1H, pyrimidine), 7.41 (d, 1H, *J* = 2Hz, H<sub>3</sub>-furan), 7.97 (br, 1H, NH, D<sub>2</sub>O-exchangeable), 8.06 (d, 1H, *J* = 2.2 Hz, H<sub>2</sub>-furan), 9.59 (br, 1H, NH, D<sub>2</sub>O-exchangeable), 13.05 (br, 1H, OH, D<sub>2</sub>O-exchangeable); MS (*m/z*, %): 436 (M<sup>+</sup>, 26); Anal. Calcd. for C<sub>18</sub>H<sub>20</sub>N<sub>4</sub>O<sub>5</sub>S<sub>2</sub> (436.51): C, 49.53; H, 4.62; N, 12.84. Found: C, 49.58; H, 4.60; N, 12.93.

**1-(6-Hydroxy-4-methoxy-7-(piperazin-1-ylsulfonyl)benzofuran-5-yl)ethanone (11)**

A mixture of compound **3** (0.01 mol) and potassium hydroxide (20%, 30 mL) was heated under reflux for about 4h., then cooled and poured into ice/ HCl. The obtained product was filtered off, washed several time with water and crystallized from ethanol as white powder; m.p. > 300 °C; IR

$\tilde{\nu}/\text{cm}^{-1}$ : 3165 (OH), 3124 (NH), 2922, 2841 (CH-aliph.), 1666 (C=O); <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>)  $\delta/\text{ppm}$ : 2.58 (s, 3H, COCH<sub>3</sub>), 2.68–3.33 (m, 8H, piperazine), 4.29 (s, 3H, OCH<sub>3</sub>), 7.50 (d, 1H, *J* = 2.02 Hz, H<sub>3</sub>-furan) 7.81 (d, 1H, *J* = 2.01 Hz, H<sub>2</sub>-furan), 10.26 (br, 1H, NH, D<sub>2</sub>O-exchangeable), 13.13 (br, 1H, OH, D<sub>2</sub>O-exchangeable); MS (*m/z*, %): 354 (M<sup>+</sup>, 41); Anal. Calcd. for C<sub>15</sub>H<sub>18</sub>N<sub>2</sub>O<sub>6</sub>S (354.38): C, 50.84; H, 5.12; N, 7.90. Found: C, 50.94; H, 5.21; N, 7.84.

**3-(Dimethylamino)-1-(6-hydroxy-4-methoxy-7-(piperazin-1-ylsulfonyl)benzofuran-5-yl)prop-2-en-1-one (12)**

A mixture of compound **11** (0.01 mol) and dimethylformamide dimethylacetal (0.015 mol) in xylene (15 mL) was heated under reflux for 3h., the obtained product was filtered off, washed with petroleum ether and crystallized from ethanol as yellow crystals; m.p. 149–150 °C; IR  $\tilde{\nu}/\text{cm}^{-1}$ : 3200 (br, NH/OH), 2926, 2846 (CH-aliph.), 1664 (C=O); <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>)  $\delta/\text{ppm}$ : 2.06 (s, 6H, 2CH<sub>3</sub>), 2.54–3.43 (m, 8H, piperazine), 3.99 (s, 3H, OCH<sub>3</sub>), 6.78–7.81 (m, 4H, CH=CH + furan-H), 10.26 (br, 1H, NH, D<sub>2</sub>O-exchangeable), 13.13 (br, 1H, OH, exchangeable with D<sub>2</sub>O); MS (*m/z*, %): 409 (M<sup>+</sup>, 17.3), 51 (100); Anal. Calcd. for C<sub>18</sub>H<sub>23</sub>N<sub>3</sub>O<sub>6</sub>S (409.46) C, 52.80; H, 5.66; N, 10.26. Found: C, 52.71; H, 5.73; N, 10.46.

**3-(4-Chlorophenyl)-1-(6-hydroxy-4-methoxy-7-(piperazin-1-ylsulfonyl)benzofuran-5-yl)prop-2-en-1-one (13)**

A mixture of **11** (0.01 mol), 4-chlorobenzaldehyde and piperidine (0.5 mL) in ethanol (30 mL) was heated under reflux for 4h. The solid obtained was collected and recrystallized from ethanol as a yellow powder; m.p. 178–180 °C; IR  $\tilde{\nu}/\text{cm}^{-1}$ : 3159 (br, NH/OH); 2954, 2823 (CH-aliph.), 1660 (C=O); <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta/\text{ppm}$ : 2.66–3.18 (m, 8H, piperazine), 3.91 (s, 3H, OCH<sub>3</sub>), 6.80–7.85 (m, 8H, CH=CH + 4Ar-H + 2furan-H), 10.61 (br, 1H, NH, D<sub>2</sub>O-exchangeable), 13.60 (br, 1H, OH, D<sub>2</sub>O-exchangeable); MS (*m/z*, %): 477 (M<sup>+</sup>, 72); Anal. Calcd. for C<sub>22</sub>H<sub>21</sub>ClN<sub>2</sub>O<sub>6</sub>S (476.93): C, 55.40; H, 4.44; N, 5.87. Found: C, 55.52; H, 4.33; N, 5.96.

**5-(5-(4-Chlorophenyl)-1-phenyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methoxy-7-(piperazin-1-ylsulfonyl)benzofuran-6-ol (14)**

A mixture of **13** (0.01 mol) and phenylhydrazine (0.01 mL) in ethanol (30 mL) was heated under reflux for 3h. The reaction mixture was cooled, the solid product was filtered off and crystallized from ethanol as a brown powder; m.p. 133–135 °C; IR  $\tilde{\nu}/\text{cm}^{-1}$ : 3255 (br, NH/OH), 2924, 2854 (CH-aliph.); <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>)  $\delta/\text{ppm}$ : 2.73–3.58 (m, 10H, 8 piperazine-H + 2 pyrazoline-H), 4.00 (s, 3H, OCH<sub>3</sub>), 4.80 (d, 1H, pyrazoline-H), 6.77–8.55 (m, 11H, 9Ar-H + 2 furan-H), 9.36 (br, 1H, NH, D<sub>2</sub>O-exchangeable), 14.17 (br, H, OH, D<sub>2</sub>O-exchangeable); MS (*m/z*, %): 567 (M<sup>+</sup>, 29); Anal. Calcd. for C<sub>28</sub>H<sub>27</sub>ClN<sub>4</sub>O<sub>5</sub>S (567.06) C, 59.31; H, 4.80; N, 9.88. Found: C, 59.54; H, 4.67; N, 9.93.



## General Procedure for the Synthesis of 7-substitued furo[3,2-g] Chromen-6-carbonitrile Derivatives 15a,b

A mixture of **14** (0.01 mol), malonitrile or ethyl cyanoacetate (0.01 mol) and piperidine (0.5 mL) in ethanol (20 mL) was heated under reflux for 3h. The solid product was collected and recrystallized from ethanol to give the corresponding compounds **15a, b**.

### 7-Imino-4-methoxy-5-methyl-9-(piperazin-1-ylsulfonyl)-7H-furo[3,2-g]chromene-6-carbonitrile (15a)

Brown crystals; m.p. > 300 °C; IR  $\tilde{\nu}/\text{cm}^{-1}$ : 3341, 3302 (2NH), 2925 (CH-aliph.), 2196 (C≡N);  $^1\text{H}$  NMR (DMSO- $d_6$ )  $\delta/\text{ppm}$ : 2.44 (s, 3H, CH<sub>3</sub>), 2.78–3.54 (m, 8H, piperazine), 4.08 (s, 3H, OCH<sub>3</sub>), 6.77 (d, 1H,  $J = 2.0$  Hz, furan-H<sub>3</sub>), 7.36 (br, 1H, NH, D<sub>2</sub>O-exchangeable), 7.94 (d, 1H,  $J = 2.1$  Hz, furan-H<sub>2</sub>), 10.43 (br, 1H, NH, D<sub>2</sub>O-exchangeable); MS ( $m/z$ , %): 402 (M<sup>+</sup>, 76); Anal. Calcd. for C<sub>18</sub>H<sub>18</sub>N<sub>4</sub>O<sub>5</sub>S (402.42) C, 53.72; H, 4.51; N, 13.92. Found: C, 53.62; H, 4.56; N, 13.98.

### 4-Methoxy-5-methyl-7-oxo-9-(piperazin-1-ylsulfonyl)-7H-furo[3,2-g]chromene-6-carbonitrile (15b)

Brown needles; m.p. > 300 °C; IR  $\tilde{\nu}/\text{cm}^{-1}$ : 3204 (NH), 2926 (CH-aliph.), 2221 (C≡N), 1705 (C=O of  $\alpha$ -pyrone);  $^1\text{H}$  NMR (DMSO- $d_6$ )  $\delta/\text{ppm}$ : 2.42 (s, 3H, CH<sub>3</sub>), 3.30–3.51 (m, 8H, piperazine), 3.94 (s, 3H, OCH<sub>3</sub>), 6.75 (d, 1H,  $J = 2.2$  Hz, furan-H<sub>3</sub>), 7.32 (br, 1H, NH, D<sub>2</sub>O-exchangeable), 7.94 (d, 1H,  $J = 2.1$  Hz, furan-H<sub>2</sub>); MS ( $m/z$ , %): 403 (M<sup>+</sup>, 28); Anal. Calcd. for C<sub>18</sub>H<sub>17</sub>N<sub>3</sub>O<sub>6</sub>S (403.41) C, 53.59; H, 4.25; N, 10.42. Found: C, 53.73; H, 4.32; N, 10.64.

### Synthesis of 3-amino-10-methoxy-6-(piperazin-1-ylsulfonyl)-4H-furo[3,2-g]thieno[3,4-c]chromen-4-one (16)

A mixture of **15b** (0.01 mol) and sulfur (0.01 mol) in ethanol (30 mL) containing triethylamine (0.5 mL) was heated under reflux for 3h, the obtained solid was collected and crystallized from ethanol as brown crystals; m.p. 119–120 °C; IR  $\tilde{\nu}/\text{cm}^{-1}$ : 3414, 3299 (NH/NH<sub>2</sub>), 2987, 2927 (CH-aliph.), 1702 (C=O of  $\alpha$ -pyrone);  $^1\text{H}$  NMR (DMSO- $d_6$ )  $\delta/\text{ppm}$ : 2.76–3.51 (m, 8H, piperazine), 3.86 (s, 3H, OCH<sub>3</sub>), 6.75–7.94 (m, 5H, 2 furan-H + thiophen-H + NH<sub>2</sub>), 9.32 (br, 1H, NH, D<sub>2</sub>O-exchangeable); MS ( $m/z$ , %): 435 (M<sup>+</sup>, 44); Anal. Calcd. for C<sub>18</sub>H<sub>17</sub>N<sub>3</sub>O<sub>6</sub>S<sub>2</sub> (435.47) C, 49.65; H, 3.93; N, 9.65. Found: C, 49.83; H, 3.81; N, 9.76.

### Synthesis of 4-amino-11-methoxy-2-(4-methoxyphenyl)-5-oxo-7-(piperazin-1-ylsulfonyl)-5H-benzo[c]furo[3,2-g]chromene-3-carbonitrile (17)

A mixture of **15b** (0.01 mol), 4-methoxybenzylidene-malonitrile (0.01 mol) and piperidine (1 mL) in dimethyl formamide (20 mL) was heated under reflux for 4h. The product was filtered off and crystallized from ethanol as yellow crystals; m.p. 149–150 °C; IR  $\tilde{\nu}/\text{cm}^{-1}$ : 3360, 3139

(NH/NH<sub>2</sub>), 2928 (CH-aliph.), 2208 (C≡N), 1707 (C=O);  $^1\text{H}$  NMR (DMSO- $d_6$ )  $\delta/\text{ppm}$ : 2.86–3.48 (m, 8H, piperazine), 3.56 (s, 3H, OCH<sub>3</sub>), 3.78 (s, 3H, OCH<sub>3</sub>), 7.31–7.88 (m, 9H, 5 Ar-H + 2 furan-H + NH<sub>2</sub>), 9.13 (br, 1H, NH, D<sub>2</sub>O-exchangeable); MS ( $m/z$ , %): 560 (M<sup>+</sup>, 54); Anal. Calcd. for C<sub>28</sub>H<sub>24</sub>N<sub>4</sub>O<sub>7</sub>S (560.58) C, 59.99; H, 4.32; N, 9.99. Found: C, 59.73; H, 4.30; N, 9.80.

## Antimicrobial Assay

The synthesized compounds were screened *in vitro* for their antimicrobial activities against strains of bacteria and strains of fungi by the agar diffusion technique.<sup>[1]</sup> A 1 mg/mL solution in dimethylformamide was used. The bacteria and fungi were maintained on nutrient agar and Czapek's-Dox agar media, respectively. DMF showed no inhibition zones. The agar media were inoculated with different microorganisms culture tested. After 24h of incubation at 37 °C for bacteria and 48h of incubation at 28 °C for fungi, the diameter of inhibition zone (mm) was measured. Chloramphenicol and Terbinafin used as references for antibacterial and antifungal activities, respectively.

## REFERENCES

- [1] S.Y. Abbas, M.A.M. Sh. El-Sharief, W. M. Basyouni, I. M. I. Fakhr, E. W. El-Gammal, *Eur. J. Med. Chem.* **2013**, *64*, 111.
- [2] M. H. Helal, S. Y. Abbas, M. A. Salem, A. A. Farag, Y. A. Ammar, *Med. Chem. Res.* **2013**, *22*, 5598.
- [3] M. A. M. Sh. El-Sharief, S. Y. Abbas, K. A. M. El-Bayouki, E. W. El-Gammal, *Eur. J. Med. Chem.* **2013**, *67*, 263.
- [4] K. Asoh, M. Kohchi, I. Hyoudoh, T. Otsuka, M. Masubuchi, K. Kawasaki, H. Ebiike, Y. Shiratori, T. A. Fukami, O. Kondoh, T. Tsukaguchi, N. Ishii, Y. Aoki, N. Shimma, M. Sakaitani, *Bioorg. Med. Chem. Lett.* **2009**, *19*, 1753.
- [5] S. K. Lee, B. Cui, R. R. Mehta, A. D. Kinghorn, J. M. Pezutto, *Chem. Biol. Interact.* **1998**, *115*, 215.
- [6] M. Koca, S. Servi, C. Kirilmis, M. Ahmedzade, C. Kazas, *Eur. J. Med. Chem.* **2005**, *40*, 1351.
- [7] J. Nawrot-Modranka, E. Nawrot, J. Graczyk, *Eur. J. Med. Chem.* **2006**, *41*, 1301.
- [8] B-d. Wang, Z-Y. Yang, T-r. Li, *Bioorg. Med. Chem.* **2006**, *14*, 6012.
- [9] L. Pisco, M. Kordian, K. Peseke, H. Feist, D. Michalik, E. Estrada, J. Carvalho, G. Hamilton, D. Rando, J. Quincoces, *Eur. J. Med. Chem.* **2006**, *41*, 401.
- [10] M. Ghate, R. A. Kusanur, M. V. Kulkarni, *Eur. J. Med. Chem.* **2005**, *40*, 882.
- [11] B. H. Havsteen, *Pharmacol Ther.* **2002**, *96*, 67.
- [12] A. K. Gadad, C. S. Mahajanshetti, S. Nimbalkar, A. Raichurkar, *Eur. J. Med. Chem.* **2000**, *35*, 853.

- [13] T. Narasaiaha, D. Subba Raa, K. Venkata Ramanaa, S. Adamb, C. Naga Raju, *Der Pharma Chemica*, **2012**, *4*, 1582.
- [14] I. Argyropoulou, A. Geronikaki, P. Vicini, F. Zani, *ARKIVOC* **2009**, (vi), 89.
- [15] Z. Franca, V. Paola, *Archiv der Pharmazie*. **1998**, *331*, 219.
- [16] S. Alyar, N. Karacan, *J. Enzyme Inhib. Med. Chem.* **2009**, *24*, 986.
- [17] A. A. Farag, S. N. Abd-Alrahman, G. F. Ahmed, R. M. Ammar, Y. A. Ammar, S. Y. Abbas, *Arch. Pharm. Life Sci.* **2012**, *345*, 703.
- [18] A. A. Farag, Y. A. Ammar, A.-A. G. El-Sehemi, H. Kh. Thabet, N. A. Hassan, A. Kh. Samy, *J. Chem. Res.* **2011**, *163*, 163.
- [19] Y. A. Ammar, M. M. Aly, A.-A. G. Al-Sehemi, M. A. Salem, M. S. A. El-Gaby, *J. Chinese chem. Soc.* **2009**, *183*, 1064.
- [20] M. M. Ghorab, E. Noaman, M. M. F. Ismail, H. I. Heiba, Y. A. Ammar, M. Y. Sayed, *Arzneim-Forsch /Drug Research* **2006**, *56*, 405.
- [21] S. Y. Abbas, A. A. Farag, Y. A. Ammar, A. A. Atrees, A. F. Mohamed, A. A. El-Henawy, *Monatsh Chem.* **2013**, *144*, 1725.
- [22] Y. A. Ammar, H. M. El-Sehrawi, H. S. A. El-Zahabi, T. Z. Shawer, M. M. F. Ismail, *Der Pharma Chemica* **2012**, *4*, 2140.
- [23] Y. A. Ammar, H. Kh. Thabet, M. M. Aly, Y. A. Mohamed, M. A. Ismail, M. A. Salem, *Phosphorus sulfur and silicon* **2010**, *185*, 743.
- [24] M. H. Helal, G. A. M. El-Hag Ali, A. A. Ali, Y. A. Ammar, *J. Chem. Res.* **2010**, *465*, 465.
- [25] G. A. M. El-Hag Ali, M. H. Helal, Y. A. Mohamed, A. A. Ali, Y. A. Ammar, *J. Chem. Res.* **2010**, *469*, 459.
- [26] M. H. A. Elgamal, N. M. M. Shalaby, H. Duddeck, D. Rasenbaum, *J. Heterocyclic Chem.* **1987**, *24*, 721.